Press releases
- The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indications
- First‑in‑class METTL3 inhibitor reprograms malignant progenitor cells by modulating mRNA methylation
Read more
STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announced a strategic collaboration with Alida Biosciences Inc. (AlidaBio), a company at the forefront of epitranscriptomics and RNA modification analysis.
Read more
STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announced the appointment of accomplished cancer biologist Dr. Eric Martin, PhD, as Chief Development Officer (CDO).
Read more
STC-15 has demonstrated durable clinical activity and tolerability to progress into a combination study with a checkpoint inhibitor
Collaboration enables Phase 1b/2 study with STORM’s lead product, STC-15 in combination with Coherus’s next generation PD-1 inhibitor, LOQTORZI® (toripalimab) in patients with NSCLC, HNSCC, melanoma, and endometrial cancer
Atif Abbas, M.D. joins as Chief Medical Officer
Read more
STC-15 is well tolerated and demonstrates promising signs of clinical activity observed in multiple tumor types
Gene expression data shows upregulation of innate immunity pathways
Tumor regressions observed at all dose levels, 60-200 mg TIW
Read more